Antitumor Activity of γδ T Cells Reactive against Cytomegalovirus-Infected Cells in a Mouse Xenograft Tumor Model

被引:35
作者
Devaud, Christel
Bilhere, Eric
Loizon, Severine
Pitard, Vincent
Behr, Charlotte
Moreau, Jean-Francois [2 ]
Dechanet-Merville, Julie
Capone, Myriam [1 ]
机构
[1] Univ Bordeaux 2, CNRS, UMR 5164, F-33076 Bordeaux, France
[2] CHU Bordeaux, Lab Immunol & Immunogenet, Bordeaux, France
关键词
INFILTRATING LYMPHOCYTES; ALLOGRAFT RECIPIENTS; SCID MICE; IN-VITRO; CARCINOMA; CANCER; VIVO; IMMUNOTHERAPY; RECOGNITION; EXPRESSION;
D O I
10.1158/0008-5472.CAN-08-3037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
gamma delta T cells recognize stress-induced autoantigens and contribute to immunity against infections and cancer. Our previous study revealed that V delta 2-negative ((neg)) gamma delta T lymphocytes isolated from transplant recipients infected by cytomegalovirus (CMV) killed both CMV-infected cells and HT29 colon cancer cells in vitro. To investigate the antitumor effects of V delta 2(neg) clones in vivo, we generated hypodermal HT29 tumors in immunodeficient mice. Concomitant injections of V delta 2(neg)clones, in contrast to V delta 2(+) cells, prevented the development of HT29 tumors. V delta 2(neg) clones expressed chemokine C-C motif receptor 3 (CCR3) and migrated in vitro in response to chemokines secreted by HT29 cells, among which were the CCR3 ligands macrophage inflammatory protein-1 delta and monocyte chemoattractant protein-4. More importantly, a systemic i.p. treatment with V delta 2(neg) clones delayed the growth of HT29 s.c. tumors. The effect of in vivo gamma delta T-cell passive immunotherapy on tumor growth could be reverted by addition of a blocking anti-CCR3 antibody. gamma delta T-cell passive immunotherapy was dependent on the cytotoxic activity of the gamma delta effectors toward their targets because V delta 2(neg) clones were not able to inhibit the growth of A431 hypodermal tumors. Our findings suggest that CMV-specific V delta 2(neg) cells could target in vivo cancer cells, making them an attractive candidate for antitumor immunotherapy. [Cancer Res 2009;69(9):3971-8]
引用
收藏
页码:3971 / 3978
页数:8
相关论文
共 33 条
[21]   Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenografts in SCID mice [J].
Lozupone, F ;
Pende, D ;
Burgio, VL ;
Castelli, C ;
Spada, M ;
Venditti, M ;
Luciani, F ;
Lugini, L ;
Federici, C ;
Ramoni, C ;
Rivoltini, L ;
Parmiani, G ;
Belardelli, F ;
Rivera, P ;
Marcenaro, S ;
Moretta, L ;
Fais, S .
CANCER RESEARCH, 2004, 64 (01) :378-385
[22]   Human intestinal V delta 1(+) T lymphocytes recognize tumor cells of epithelial origin [J].
Maeurer, MJ ;
Martin, D ;
Walter, W ;
Liu, KH ;
Zitvogel, L ;
Halusczcak, K ;
Rabinowich, H ;
Duquesnoy, R ;
Storkus, W ;
Lotze, MT .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) :1681-1696
[23]  
MALKOVSKA V, 1992, CANCER RES, V52, P5610
[24]  
PENN I, 1979, NEW ENGL J MED, V301, P385
[25]   Activation of Vγ9Vδ2 T cells by NKG2D [J].
Rincon-Orozco, B ;
Kunzmann, V ;
Wrobel, P ;
Kabelitz, D ;
Steinle, A ;
Herrmann, T .
JOURNAL OF IMMUNOLOGY, 2005, 175 (04) :2144-2151
[26]   Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy [J].
Sato, K ;
Kimura, S ;
Segawa, H ;
Yokota, A ;
Matsumoto, S ;
Kuroda, J ;
Nogawa, M ;
Yuasa, T ;
Kiyono, Y ;
Wada, H ;
Maekawa, T .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (01) :94-99
[27]   In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model [J].
Sicard, H ;
Ingoure, S ;
Luciani, B ;
Serraz, C ;
Fournié, JJ ;
Bonneville, M ;
Tiollier, J ;
Romagné, F .
JOURNAL OF IMMUNOLOGY, 2005, 175 (08) :5471-5480
[28]   Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma [J].
Sicard, H ;
Al Saati, T ;
Delsol, G ;
Fournié, JJ .
MOLECULAR MEDICINE, 2001, 7 (10) :711-722
[29]   Self/non-self discrimination by human γδ T cells:: simple solutions for a complex issue? [J].
Thedrez, Aurelie ;
Sabourin, Caroline ;
Gertner, Julie ;
Devilder, Marie-Claire ;
Allain-Maillet, Sophie ;
Fournie, Jean-Jacques ;
Scotet, Emmanuel ;
Bonneville, Marc .
IMMUNOLOGICAL REVIEWS, 2007, 215 :123-135
[30]   γδ T cells for immune therapy of patients with lymphoid malignancies [J].
Wilhelm, M ;
Kunzmann, V ;
Eckstein, S ;
Reimer, P ;
Weissinger, F ;
Ruediger, T ;
Tony, HP .
BLOOD, 2003, 102 (01) :200-206